Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma

BACKGROUND: Median overall survival is 12 to 15 months in patients with metastatic adrenal cortical carcinoma (ACC). Etoposide, doxorubicin, and cisplatin with or without the adrenolytic agent mitotane is considered the best first-line approach in this context, but has limited activity and no curati...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Kevin C, Chintakuntlawar, Ashish V, Hilger, Crystal, Bancos, Irina, Morris, John C, Ryder, Mabel, Smith, Carin Y, Jenkins, Sarah M, Bible, Keith C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326479/
https://www.ncbi.nlm.nih.gov/pubmed/32666013
http://dx.doi.org/10.1210/jendso/bvaa069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326479/
https://www.ncbi.nlm.nih.gov/pubmed/32666013
http://dx.doi.org/10.1210/jendso/bvaa069

Ejemplares similares